Last reviewed · How we verify

NCT03871218

Effect of Hyaluronic-acid on the Healing After Free Gingival Graft

Completed Phase 2 Last updated 30 July 2019
What this trial tests

Phase 2 trial testing Hyaluronic acid group in Gingival Recession in 40 participants. Completed in 1 December 2018.

Timeline
1 April 2017
Primary endpoint
1 April 2018
1 December 2018

Quick facts

Lead sponsorGazi University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 April 2017
Primary completion1 April 2018
Estimated completion1 December 2018
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gazi University

Who can join

Adults 25 to 45, any sex, with Gingival Recession. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluated the effect of topical hyaluronic acid (HA) application on free gingival graft (FGG) donor and recipient sites during the early wound healing period with laser Doppler flowmetry (LDF) and to investigate the effect of HA application on the dimensional change of the graft.Participants were randomly classified into the test group (TG) and control group (CG). HA was applied to both donor and recipient sites in 20 patients who formed the TG, whereas HA was not applied to the 20 patients who formed the CG.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gingival Recession

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing